UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

UniQure is moving forward with plans to seek FDA approval for its groundbreaking gene therapy targeting Huntington's disease, following a contentious debate with agency leaders over trial data. This move underscores the company's determination to bring a potential new treatment to patients despite regulatory hurdles. The significance of this development lies in Huntington's disease being a debilitating condition with no effective treatments, so a successful therapy could represent a major breakthrough in managing the disease and improving patients' quality of life.